WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update
May 13, 2021 07:30 ET | Wave Life Sciences USA, Inc.
Clinical trials underway with next-generation candidates incorporating PN chemistry Clinical data from PN chemistry programs expected in 2022 In vivo ADAR editing data for AATD program on track for...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences Highlights Pipeline Progress and Expansion Leveraging New PN Backbone Chemistry Modifications
January 11, 2021 08:00 ET | Wave Life Sciences USA, Inc.
Three clinical trials to begin in 2021 with compounds containing Wave’s novel PN backbone chemistry modifications Data from ongoing PRECISION-HD and OLE clinical trials for Huntington’s disease...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences to Highlight Preclinical ADAR Editing Data and Neurology Programs at TIDES and OTS Annual Meetings
September 15, 2020 07:30 ET | Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences Reports Second Quarter 2020 Financial Results and Provides Business Update
August 10, 2020 07:30 ET | Wave Life Sciences USA, Inc.
Data from 32 mg cohorts of both PRECISION-HD trials and PRECISION-HD OLE trials expected in 1Q 2021 C9orf72 and SNP3 clinical trial applications on track to be submitted in 4Q 2020 ADAR editing...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences to Highlight PRISM Platform Advancements and Preclinical Neurology Pipeline During Analyst and Investor Research Webcast
August 06, 2020 08:00 ET | Wave Life Sciences USA, Inc.
Neurology pipeline discussion will include new preclinical data for C9orf72 program for ALS and FTD Platform advancements to be shared include new in vivo RNA editing data Live webcast scheduled for...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences Appoints Dr. Ken Rhodes as Senior Vice President, Therapeutics Discovery
May 18, 2020 07:30 ET | Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 18, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
FTD, LLC Announces Appointment of New CEO
March 26, 2020 09:26 ET | FTD LLC
DOWNERS GROVE, Ill., March 26, 2020 (GLOBE NEWSWIRE) -- FTD, LLC, a leader in the floral industry for more than a century, today announced the appointment of Charlie Cole as its Chief Executive...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Publications on AAV Gene Therapy Approach to Treating Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) in the Journal Molecular Therapy Nucleic Acids
February 15, 2019 07:24 ET | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 15, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
Equillium_Transparent-300px.png
Equillium Granted U.S. FDA Fast Track Designation for EQ001 for the Treatment of Acute Graft-Versus-Host Disease
December 19, 2018 08:06 ET | Small Logo
LA JOLLA, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the...
WAVE LOGO NEW COLOR SWOOSH.jpg
Preclinical Data Supporting Wave Life Sciences ALS and FTD Programs Presented at 28th International Symposium on ALS/MND
December 11, 2017 07:00 ET | Wave Life Sciences
CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious,...